Scleroderma Drug Developer iBio Announces U.S. Patent for iBioModulator™ Thermostable Immunomodulator Protein Portfolio

iBio, Inc. recently announced the release of a U.S. patent for a new thermostable immunomodulator protein portfolio called iBioModulator™.

The company’s iBioModulator™ thermostable immunomodulator protein patents, entitled “Yersinia pests Antigens, Vaccine Compositions and Related Methods,” (Serial No. 8,945,580), includes statements about plague antigens, vaccine compositions, and a technique that produces a protective immune effect to the antigen.

Evidence from data published in the journal Vaccine showed that a plague vaccine including the iBioModulator™ thermostable immunomodulator protein and made with the iBioLaunch™ platform that provided gene expression in green plants was able to protect primates against a pneumonic plague (aerosolized Y. pests).

This new patent provides an additional portfolio to the plague vaccine iBioModulator™ thermostable immunomodulator protein (U.S. Serial No. 8,404,252, European Serial No. 2178558). Researchers at Fraunhofer USA Center for Molecular Biotechnology were responsible for the discovery.

iBioModulator™ thermostable immunomodulator protein patents are part of iBio’s large patent portfolio that includes the creation of vaccines for infectious diseases such as plague, anthrax, human papilloma virus, and influenza. Studies in animal models have found that this technology when used in combination with vaccine antigens increases and extended the effect of the immune system response produced by vaccines.

[adrotate group=”3″]

“The achievements with plague vaccine are just one application of iBio’s core technology — the iBioLaunch™ gene expression platform — that enables advantageous plant-based development and manufacture of monoclonal antibodies and other therapeutics, as well as vaccines,” said Robert Erwin, iBio’s president in a recent press release.

“In its application to seasonal influenza vaccines, the speed of our proprietary technology would allow determination of the identity of each season’s predominant influenza virus to be made substantially closer in time to the flu season, decreasing the opportunities for viral mutation and thereby increasing the likely efficacy of that year’s vaccine and decreasing flu-caused illnesses and deaths. As we pursue our current primary focus using iBioLaunch™ technology for development, manufacture and clinical trials of products against various fibrotic diseases — including idiopathic pulmonary fibrosis and scleroderma — we also continue our interest and activities to partner with others for the application of iBioLaunch™ technology to vaccines.”